Breast Cancer

Three clinical trials conducted in postmenopausal women with hormone receptor (HR)-positive breast cancer showed no advantage to extending endocrine therapy beyond an initial 5 years.
In metastatic hormone receptor (HR)-positive breast cancer, adding everolimus to fulvestrant overcomes resistance to aromatase inhibitor therapy.
Updated guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer confirm older conservative guidance.
A sophisticated gene signature test has been shown to enhance the prediction of the clinical efficacy of chemotherapy in women with early-stage breast cancer, according to results of the recent phase 3 MINDACT study. The findings will enable many women to safely avoid chemotherapy.
A new cyclin-dependent kinase 4/6 inhibitor has received approval as first-line therapy for advanced breast cancer based on impressive results from the randomized, phase 3 MONALEESA-2 study.
Although 5 years of neoadjuvant endocrine therapy improves disease-free survival in patients with early-stage breast cancer, the optimal duration of adjuvant therapy beyond 5 years has yet to be established. Results of a new study, suggesting that longer is not necessarily better, provide further insight on this topic.
An evaluation of more than 200 patients with breast cancer showed a near doubling of the risk for contralateral disease with dense breast tissue. This information may help clinicians counsel patients on their personal risk and options for treatment and surveillance.
Adding pertuzumab to standard therapy in women with HER2-positive/HR-positive locally advanced or metastatic breast cancer increased PFS, with no new safety signals identified.
No significant difference was found in survival between BRCA gene carriers and noncarriers among young patients with breast cancer. In addition, a consistent survival advantage was found in favor of BRCA carriers presenting with triple-negative breast cancer.
New data confirm the heterogeneity of HER2-positive breast cancer and may identify a subgroup of patients who benefit from dual HER2 blockade without the use of chemotherapy.
Page 1 of 13
Results 1 - 10 of 121